CoChat

Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression

Open access
Hunsberger, Holly C., Weitzner, Daniel S., Rudy, Carolyn C., Hickman, James E., Libell, Eric M., Speer, Rebecca R., Gerhardt, Greg A., Reed, Miranda N. · 2015 · Journal of Neurochemistry
Cited by 86

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Hyperexcitability of the hippocampus is a commonly observed phenomenon in the years preceding a diagnosis of Alzheimer's disease (AD). Our previous work suggests a dysregulation in glutamate neurotransmission may mediate this hyperexcitability, and glutamate dysregulation correlates with cognitive deficits in the rT g(TauP301L)4510 mouse model of AD. To determine whether improving glutamate regulation would attenuate cognitive deficits and AD‐related pathology, TauP301L mice were treated with riluzole (~ 12.5 mg/kg/day p.o.), an FDA‐approved drug for amyotrophic lateral sclerosis that lowers extracellular glutamate levels. Riluzole‐treated TauP301L mice exhibited improved performance in the water radial arm maze and the Morris water maze, associated with a decrease in glutamate release and an increase in glutamate uptake in the dentate gyrus, cornu ammonis 3 (CA 3), and cornu ammonis 1 (CA 1) regions of the hippocampus. Riluzole also attenuated the TauP301L‐mediated increase in hippocampal vesicular glutamate transporter 1, which packages glutamate into vesicles and influences glutamate release; and the TauP301L‐mediated decrease in hippocampal glutamate transporter 1, the major transporter responsible for removing glutamate from the extracellular space. The TauP301L‐mediated reduction in PSD‐95 expression, a marker of excitatory synapses in the hippocampus, was also rescued by riluzole. Riluzole treatment reduced total levels of tau, as well as the pathological phosphorylation and conformational changes in tau associated with the P301L mutation. These findings open new opportunities for the development of clinically applicable therapeutic approaches to regulate glutamate in vulnerable circuits for those at risk for the development of AD. image TauP301L mice exhibit increased glutamate release and decreased glutamate clearance, leading to increased extracellular glutamate and excitotoxicity. Riluzole treatment reduced glutamate release and increased glutamate clearance. Improved glutamate regulation was associated with improvements in learning and memory, an increase in PSD95 expression, and a decrease in tau pathology in riluzole‐treated TauP301L mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13230

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 86

Metadata

Authors
Hunsberger, H. C., Weitzner, D. S., Rudy, C. C., Hickman, J. E., Libell, E. M., Speer, R. R., Gerhardt, G. A., & Reed, M. N.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2015-08-13
Volume
135
Issue
2
Pages
381-394
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1599577331
Cited by
86
References
18
FWCI
4.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.